The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2024 | Enhancing outcomes of patients with DLBCL treated with CAR T-cell therapy
In this video, Stefania Bramanti, MD, Humanitas Research Hospital, Rozzano, Italy, briefly discusses how CAR T-cell therapy outcomes can be improved in patients with diffuse large B-cell lymphoma (DLBCL). Administering CAR-T in patients who have received fewer prior lines of therapy will likely enhance efficacy and minimize toxicity. Dr Bramanti highlights that patients selection for CAR-T should involved stratification based on molecular prognostic factors. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
